Integra LifeSciences Holdings Corporation (IART)
NASDAQ: IART · Real-Time Price · USD
16.72
+0.10 (0.60%)
Sep 2, 2026, 3:11 PM EDT - Market open
IART Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,648 | 1,635 | 1,611 | 1,542 | 1,558 | 1,542 |
Revenue Growth | 1.60% | 1.54% | 4.47% | -1.03% | 0.99% | 12.43% |
Gross Profit Gross Profit Growth | 937.07 | 919.42 | 959.12 | 884.74 | 970.31 | 944.64 |
Operating Income Operating Income Growth | 163.4 | 145.92 | 181.98 | 111.53 | 238.92 | 199.98 |
Net Income Net Income Growth | -7.24 | -516.47 | -6.94 | 67.74 | 180.55 | 169.08 |
Earnings Per Share EPS Growth | -0.10 | -6.74 | -0.09 | 0.84 | 2.16 | 1.98 |
EPS Growth | - | - | - | -61.11% | 9.09% | 26.11% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Tissue Reconstruction Tissue Reconstruction Growth | 439.37 | 434.73 | 466.89 | 482.58 | 538.1 | 517.22 |
Specialty Surgery Specialty Surgery Growth | 1,208 | 1,201 | 1,144 | 1,059 | 1,020 | 1,025 |
Total Total Growth | 1,648 | 1,635 | 1,611 | 1,542 | 1,558 | 1,542 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 274.08 | 263.74 | 273.57 | 309.1 | 456.66 | 513.45 |
Total Debt Total Debt Growth | 2,050 | 2,035 | 1,986 | 1,684 | 1,615 | 1,700 |
Net Cash (Debt) Net Cash Growth | -1,776 | -1,771 | -1,713 | -1,374 | -1,159 | -1,186 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -23.08 | -23.10 | -22.24 | -17.11 | -13.87 | -13.88 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 85.33 | 50.38 | 129.38 | 139.96 | 264.47 | 312.43 |
Capital Expenditures CapEx Growth | -59.53 | -81.44 | -104.42 | -66.87 | -42.34 | -48.02 |
Free Cash Flow Free Cash Flow Growth | 25.8 | -31.05 | 24.96 | 73.09 | 222.13 | 264.41 |
Free Cash Flow Growth | - | - | -65.84% | -67.09% | -15.99% | 60.30% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 56.87% | 56.23% | 59.55% | 57.39% | 62.29% | 61.24% |
Operating Margin | 9.92% | 8.92% | 11.30% | 7.23% | 15.34% | 12.96% |
Pretax Margin | -0.01% | -34.46% | -1.13% | 5.26% | 13.73% | 13.92% |
Profit Margin | -0.44% | -31.58% | -0.43% | 4.39% | 11.59% | 10.96% |
FCF Margin | 1.57% | -1.90% | 1.55% | 4.74% | 14.26% | 17.14% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 50.26 | 25.94 | 33.56 |
Forward PE | 6.61 | 5.21 | 8.83 | 12.94 | 16.16 | 20.19 |
P/FCF Ratio | 51.75 | - | 70.10 | 46.58 | 21.08 | 21.46 |
PS Ratio | 0.81 | 0.59 | 1.09 | 2.21 | 3.01 | 3.68 |